Fig 4. Serum levels of circulating miR-107 are unsuitable to predict outcome in early-stage HCC patients.
(A) HCC patients with miR-107 serum levels above or below the 50th percentile (3.12) have a comparable overall survival. (B) HCC patients with miR-107 serum levels above the ideal prognostic cut-off value (9.82) show a non-significant trend (p = 0.119) towards an impaired survival.